Drugs / rMenB+OMV NZ vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04502693 | Aug 2020 → Sep 2022 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04502693 ↗ |
| Modality | Vaccine | “rMenB+OMV NZ vaccine was administered intramuscularly.” NCT04502693 ↗ |
| Route | Intramuscular | “rMenB+OMV NZ vaccine was administered intramuscularly.” NCT04502693 ↗ |